Effect of Daptomycin on Local Interleukin-6, Matrix Metalloproteinase-9, and Metallopeptidase Inhibitor 1 in Patients With MRSA-Infected Diabetic Foot

被引:13
作者
Ambrosch, Andreas [1 ,2 ]
Halevy, Daniel [3 ]
Fwity, Boushra [2 ]
Brin, Thomas [2 ]
Lobmann, Ralf [3 ]
机构
[1] Inst Lab Med Microbiol & Hyg, Regensburg, Germany
[2] Inst Lab Med & Microbiol, Bremerhaven, Germany
[3] Stuttgart Burgerhosp, Stuttgart, Germany
关键词
daptomycin; diabetic foot; MMP-9; TIMP-1; MRSA; RESISTANT STAPHYLOCOCCUS-AUREUS; COMPLICATED SKIN; RISK-FACTORS; VANCOMYCIN; EXPRESSION; ULCERS; TRIAL;
D O I
10.1177/1534734613490506
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Infection is a major cause of the diabetic foot syndrome being aggravating by the increased burden of multiresistant germs like methicillin-resistant Staphylococcus aureus (MRSA). Maximizing positive outcome for serious MRSA infections requires an aggressive treatment approach and a careful monitoring of the healing process. Therefore, we examined 8 patients with MRSA-infected diabetic foot syndrome Wagner classification grades 2 or 3 (corresponding to the Texas classification stage 2 and 3) during antibiotic treatment with daptomycin. We documented the wound size and obtained samples of wound secretion for analyses of pro-inflammatory interleukin-6 (IL-6), protease (matrix metalloproteinase-9 [MMP-9]), and antiprotease activity (metallopeptidase inhibitor 1 [TIMP-1]). During the course of anti-MRSA therapy, a decrease in the concentration of local IL-6 within the first 3 days followed by a drop of MMP-9 and an increase of TIMP-1 was observed. Finally, a reduction of wound size could be documented. The present data show that efficient antimicrobial treatment with daptomycin leads to a number of beneficial processes at the molecular level of wound healing in MRSA-infected diabetic foot ulcers.
引用
收藏
页码:100 / 105
页数:6
相关论文
共 29 条
  • [1] Interleukin-6 concentrations in wound fluids rather than serological markers are useful in assessing bacterial triggers of ulcer inflammation
    Ambrosch, Andreas
    Lobmann, Ralf
    Pott, Andreas
    Preissler, Jurgen
    [J]. INTERNATIONAL WOUND JOURNAL, 2008, 5 (01) : 99 - 106
  • [2] The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections
    Arbeit, RD
    Maki, D
    Tally, FP
    Campanaro, E
    Eisenstein, BI
    [J]. CLINICAL INFECTIOUS DISEASES, 2004, 38 (12) : 1673 - 1681
  • [3] Gelatinase concentration in tears of corneal-grafted patients
    Barro, CD
    Romanet, JP
    Fdili, A
    Guillot, M
    Morel, F
    [J]. CURRENT EYE RESEARCH, 1998, 17 (02) : 174 - 182
  • [4] Wound healing and its impairment in the diabetic foot
    Falanga, V
    [J]. LANCET, 2005, 366 (9498) : 1736 - 1743
  • [5] In vitro activity of daptomycin against gram-positive European clinical isolates with defined resistance determinants
    Fluit, AC
    Schmitz, FJ
    Verhoef, J
    Milatovic, D
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (03) : 1007 - 1011
  • [6] Bactericidal agents in the treatment of MRSA infections - the potential role of daptomycin
    French, G. L.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 58 (06) : 1107 - 1117
  • [7] German Diabetes Association, OFF STAND WOUND INF
  • [8] Comparison of microbiological results of needle puncture vs. superficial swab in infected diabetic foot ulcer with osteomyelitis
    Kessler, L
    Piemont, Y
    Ortega, F
    Lesens, O
    Boeri, C
    Averous, C
    Meyer, R
    Hansmann, Y
    Christmann, D
    Gaudias, J
    Pinget, M
    [J]. DIABETIC MEDICINE, 2006, 23 (01) : 99 - 102
  • [9] Lavery L A, 1996, J Foot Ankle Surg, V35, P528
  • [10] Skin and soft tissue infections in hospitalised patients with diabetes: culture isolates and risk factors associated with mortality, length of stay and cost
    Lipsky, B. A.
    Tabak, Y. P.
    Johannes, R. S.
    Vo, L.
    Hyde, L.
    Weigelt, J. A.
    [J]. DIABETOLOGIA, 2010, 53 (05) : 914 - 923